196 results on '"De Ponti, Fabrizio"'
Search Results
2. Drug Interactions with Contraceptives
3. Using artificial intelligence to create diverse and inclusive medical case vignettes for education
4. Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
5. Serotonin Modulation of Gastrointestinal Motility
6. Authors’ Reply to Cappello et al. Comment on: “Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System”
7. Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety
8. Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice
9. Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
10. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the Fda Adverse Event Reporting System
11. Antipsychotics and Drug-Induced Liver Injury
12. Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study
13. Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People
14. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
15. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
16. Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
17. Drug utilization research and pharmacovigilance
18. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction
19. Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants
20. Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System
21. Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
22. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
23. Developing medical artificial intelligence leaders: International university consortium approach
24. Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
25. Fluoroquinolones and Aortic Disease
26. European List of Essential Medicines for Medical Education: a protocol for a modified Delphi study
27. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
28. Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies
29. Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems
30. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
31. Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
32. Continuing medical education during pandemic waves of COVID-19: Consensus from medical faculties in Asia, Australia and Europe
33. Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements
34. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
35. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
36. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing
37. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
38. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
39. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
40. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
41. Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19
42. Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review
43. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
44. Reduced neuropsychiatric events as “beneficial reactions” to drugs: Seek associations with caution
45. Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors
46. Paraneoplastic Syndrome
47. Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
48. Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution
49. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors
50. Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.